| 63.59 -0.27 (-0.42%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 81.88 | 1-year : | 88.89 |
| Resists | First : | 70.1 | Second : | 76.11 |
| Pivot price | 65.36 |
|||
| Supports | First : | 60.4 | Second : | 50.25 |
| MAs | MA(5) : | 63.86  |
MA(20) : | 65.8 |
| MA(100) : | 54.48 |
MA(250) : | 32.38 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22.5 |
D(3) : | 22.6 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 76.76 | Low : | 9.56 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ARWR ] has closed above bottom band by 37.1%. Bollinger Bands are 15.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 64.67 - 65.07 | 65.07 - 65.36 |
| Low: | 61.15 - 61.65 | 61.65 - 62 |
| Close: | 62.93 - 63.67 | 63.67 - 64.19 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Fri, 20 Feb 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity - ChartMill
Thu, 19 Feb 2026
Aberdeen Group plc Sells 439,601 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Wed, 18 Feb 2026
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited - Finviz
Tue, 17 Feb 2026
Arrowhead Pharmaceuticals (ARWR) Investor Outlook: Exploring the 27.49% Upside Potential - DirectorsTalk Interviews
Sun, 15 Feb 2026
Public Sector Pension Investment Board Grows Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Thu, 12 Feb 2026
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 140 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 82.7 (%) |
| Shares Short | 10,790 (K) |
| Shares Short P.Month | 10,230 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.43 |
| Profit Margin | -0.3 % |
| Operating Margin | 17.2 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 5.92 |
| Sales Per Share | 5.92 |
| EBITDA (p.s.) | 0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 180 (M) |
| Levered Free Cash Flow | 96 (M) |
| PE Ratio | -6359 |
| PEG Ratio | 0 |
| Price to Book value | 18.53 |
| Price to Sales | 10.73 |
| Price to Cash Flow | 49.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|